2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. 17β-HSD

17β-HSD

17beta-HSD; 17β-hydroxysteroid dehydrogenases; 17 beta-hydroxysteroid dehydrogenase

17β-HSD (17β-Hydroxysteroid Dehydrogenases) is a class of NADPH/NAD+ dependent oxidoreductases that primarily catalyze the reversible conversion between the 17β-hydroxyl and ketone groups of steroid hormones, playing a crucial role in the synthesis, activation, and inactivation of steroids. The 17β-HSD family mainly belongs to the short-chain dehydrogenase/reductase (SDR) family, with the exception of 17β-HSD5 (AKR1C3), which belongs to the aldo-keto reductase (AKR) family. To date, 14 different mammalian 17β-HSDs have been identified, of which 12 are expressed in human tissues, exhibiting diverse tissue distributions, subcellular localizations, and catalytic preferences (oxidation or reduction).
17β-HSD1 primarily catalyzes the conversion of estrone (E1) to estradiol (E2) and is associated with breast cancer, prostate cancer, and endometriosis. 17β-HSD2 catalyzes the oxidation of E2 to E1, while also regulating the interconversion between androstenedione (A4) and testosterone (T), playing a role in osteoporosis. 17β-HSD3 promotes the conversion of A4 to T and is crucial for male sexual differentiation. 17β-HSD4 is involved in fatty acid β-oxidation and steroid hormone inactivation. Additionally, 17β-HSD5 participates in steroid hormone and prostaglandin synthesis, whereas 17β-HSD7 is involved in cholesterol and estrogen biosynthesis. 17β-HSD10 exhibits broad substrate specificity, contributing to the metabolism of fatty acids, bile acids, and neurosteroids, and has been implicated in Alzheimer's disease (AD). The development of selective inhibitors targeting specific 17β-HSD isoforms has become an important strategy in related disease research[1].

17β-HSD Related Products (130):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-19903
    ASP-9521
    		Inhibitor ≥98.0%
    ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3.
    ASP-9521
  • HY-148814
    BI-3231
    		Inhibitor 99.83%
    BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.
    BI-3231
  • HY-138557
    AKR1C3-IN-4
    		Inhibitor 99.77%
    AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.
    AKR1C3-IN-4
  • HY-107379
    AKR1C3-IN-1
    		Inhibitor 98.23%
    AKR1C3-IN-1 is a potent, highly selective inhibitor of AKR1C3, with an IC50 of 13 nM.
    AKR1C3-IN-1
  • HY-155035
    S07-1066
    		Inhibitor 99.48%
    S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells.
    S07-1066
  • HY-W005186
    6-Bromocoumarin
    		Inhibitor
    6-Bromocoumarin (compound 34) is a potential anti-bacterial agent, with no inhibition against 17β-HSD1. 6-Bromocoumarin exhibtis affinity for α and β estrogen receptors.
    6-Bromocoumarin
  • HY-W024692
    Indomethacin methylester
    		Inhibitor
    Indomethacin methylester (Compound 10; Indometacin methylester) is a potent and selective AKR1C3 inhibitor with an IC50 value of 5.67 μM. Indomethacin methylester is promising for research of postate cancer.
    Indomethacin methylester
  • HY-W267205
    3-Acetyl-7-Hydroxycoumarin
    		Inhibitor
    3-Acetyl-7-Hydroxycoumarin (Compound 2) is a high selective 17-beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor. 3-Acetyl-7-Hydroxycoumarin shows a significant improvement of the inhibitory potency, with 57% inhibition of 17β-HSD1 at 6 μM. 3-Acetyl-7-Hydroxycoumarin is promising for research of hormone-dependent diseases, such as breast cancer and endometriosis.
    3-Acetyl-7-Hydroxycoumarin
  • HY-145433
    17β-HSD1-IN-1
    		Inhibitor 99.34%
    17β-HSD1-IN-1 (Compound 1) is a highly selective 17β-HSD1 inhibitor with IC50s of 5.6 and 3155 nM for 17β-HSD1 and 17β-HSD2, respectively. 17β-HSD1-IN-1 can be used for the research of non-small cell lung cancer (NSCLC).
    17β-HSD1-IN-1
  • HY-156735
    HSD17B13-IN-2
    		Inhibitor 99.72%
    HSD17B13-IN-2 (compound 1) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-2 has cell experimental activity.
    HSD17B13-IN-2
  • HY-129583
    Lepidiline A
    		Activator 99.87%
    Lepidiline A exhibits cytotoxic activity against HL-60 cells with an IC50 value of 32.3 μM. Lepidiline A targets HSD17B1 activity, increases the bioconversion efficiency of sex hormones (including the conversion of estrogen into 17β-estradiol and 4-androsten-3,7-dione into testosterone), thereby improving the reproductive capacity of fruit flies..
    Lepidiline A
  • HY-156736
    HSD17B13-IN-3
    		Inhibitor 99.78%
    HSD17B13-IN-3 (compound 2) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-3 does not have cell experimental activity.
    HSD17B13-IN-3
  • HY-161227
    HSD17B13-IN-43
    		Inhibitor 99.68%
    HSD17B13-IN-43 (11) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-43
  • HY-103394
    TC HSD 21
    		Inhibitor 99.14%
    TC HSD 21 is a potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor with an IC50 of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.
    TC HSD 21
  • HY-157627
    HSD17B13-IN-9
    		Inhibitor 99.92%
    HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-9
  • HY-161212
    HSD17B13-IN-8
    		Inhibitor 99.97%
    HSD17B13-IN-8 (1) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with IC50 values of <0.1 μM for Estradiol and <1 μM for LTB3. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-8
  • HY-157630
    HSD17B13-IN-10
    		Inhibitor
    HSD17B13-IN-10 (Compound 464) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. HSD17B13-IN-10 can be used in the research of liver diseases.
    HSD17B13-IN-10
  • HY-128145
    HSD17B13-IN-41
    		Inhibitor
    HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.
    HSD17B13-IN-41
  • HY-159525
    Linustedastatum
    		Inhibitor
    Linustedastatum (Linustedastat) is a hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitor.
    Linustedastatum
  • HY-163243
    HSD17B13-IN-29
    		Inhibitor
    HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-29